TL;DR
This study investigated whether giving transdermal glyceryl trinitrate (GTN) to patients experiencing a transient ischemic attack (TIA) before they reached the hospital could improve their functional outcomes. The findings indicate that while GTN did lower blood pressure upon arrival, it did not lead to better functional recovery at 90 days and was associated with an increased risk of death or dependence.
What Problem Does This Paper Address?
Transient Ischemic Attacks (TIAs), often called "mini-strokes," are temporary episodes of neurological dysfunction caused by a temporary disruption of blood flow to the brain. While symptoms usually resolve quickly, TIAs are critical warning signs for future strokes. Pre-hospital interventions are increasingly being explored to improve outcomes for acute neurological events. However, the optimal management of TIAs in the pre-hospital setting, particularly regarding blood pressure management, remains an open question. This paper specifically addresses whether a pre-hospital intervention with transdermal glyceryl trinitrate (GTN), a vasodilator, could be beneficial for patients with a confirmed diagnosis of TIA, building on findings from a larger trial (RIGHT-2) that included patients with suspected stroke.
Methods
This study is a pre-specified subgroup analysis of the RIGHT-2 trial, a large, multicenter, randomized, sham-controlled, blinded-endpoint trial. The original RIGHT-2 trial enrolled 1149 patients with presumed acute stroke within 4 hours of symptom onset and randomized them to receive either a transdermal GTN patch or a sham patch. This analysis focuses on the 109 patients (9.5%) who, after investigation, were confirmed to have a diagnosis of TIA.
The primary outcome measured was the shift in the modified Rankin Scale (mRS) scores at 90 days, which assesses functional independence. This was analyzed using ordinal logistic regression. Secondary outcomes included death or dependence (mRS > 2), as well as various cognitive and quality-of-life measures. The analysis was performed on an intention-to-treat basis.
Datasets
The study utilized data from the RIGHT-2 trial, which enrolled 1149 patients with presumed acute stroke. The specific dataset for this analysis comprised 109 patients with a confirmed diagnosis of TIA. No new datasets or benchmarks were introduced.
Key Insights and Ideas
- Pre-hospital GTN doesn't improve TIA outcomes: The most significant finding is that administering GTN in the ambulance did not lead to better functional recovery for TIA patients. This challenges the potential utility of this intervention for this specific patient group.
- Increased risk of adverse outcomes: Counterintuitively, GTN was associated with a higher rate of death or dependence at 90 days. This suggests that lowering blood pressure acutely in TIA patients might be detrimental, potentially exacerbating an underlying ischemic insult.
- Blood pressure reduction is real but transient: GTN did effectively lower blood pressure upon hospital arrival, confirming its vasodilatory effect. However, this effect did not translate into improved functional outcomes.
- TIA is not benign: The study highlights that even transient ischemic events can lead to significant disability, cognitive impairment, and reduced quality of life, underscoring the importance of effective management strategies.
- Brain frailty as a factor: The presence of "brain frailty" (markers of small vessel disease, leukoaraiosis, etc.) was common in this TIA cohort, even among those who were independent at baseline. This suggests that baseline brain health might influence treatment response and future outcomes.
Key Results
- Out of 1149 RIGHT-2 participants, 109 (9.5%) were diagnosed with TIA.
- GTN lowered blood pressure by 7.4/5.2 mmHg compared to sham at hospital arrival.
- Primary Outcome: There was no significant difference in the shift of modified Rankin Scale (mRS) scores at 90 days between the GTN and sham groups (adjusted common odds ratio 1.47, 95% CI 0.70-3.11, p=0.31).
- Secondary Outcome (Death/Dependence): GTN was associated with an increased risk of death or dependence (mRS > 2) at 90 days (odds ratio 3.86, 95% CI 1.09-13.59, p=0.036). Specifically, 51.8% of GTN patients were dead or dependent versus 46.9% in the sham group.
- Other secondary outcomes, including cognitive function and quality of life, did not differ significantly between groups, except for mood, which was better in the GTN group at day 90.
Limitations and Future Work
The authors acknowledge several limitations:
- Subgroup Analysis: While pre-specified, this was a subgroup analysis, and a separate statistical analysis plan was not developed specifically for this group.
- Diagnostic Certainty: The TIA diagnosis was determined by site investigators, not centrally adjudicated, raising the possibility of misdiagnosis.
- Definition of TIA: Some diagnoses might have been based on symptom duration (<24h) rather than the tissue definition (symptoms <24h and no new infarct), potentially including mild strokes.
- Outcome as Designation: The designation of TIA was made post-randomization, meaning it could potentially be influenced by the treatment received.
- Brain Frailty: The high burden of brain frailty might have limited the potential treatment effect.
- Small Sample Size: The relatively small sample size for this subgroup analysis means findings may be due to chance, especially given some outcomes moving in opposite directions.
Future work could involve exploring different BP management strategies for TIA patients, similar to those used for ischemic stroke. The role of brain frailty as a predictor of outcomes and a potential stratification factor in future trials is also highlighted.
Summary updated